Produced by C&EN Webinars

Advancing Metabolic Drug Development: Integrated Preclinical Strategies from Discovery to IND-Enabling Studies

DATE

September 29, 2026

TIME

8:00 a.m. PT | 11:00 a.m. ET | 4:00 p.m. UK

Overview

With rapid advances in incretin biology and an evolving therapeutic landscape, modern metabolic drug programs require more than efficacy alone. Informed candidate selection requires early, rigorous assessment of translational relevance, tolerability, target exposure, and safety to guide development decisions.

In this webinar, attendees will learn how integrated preclinical strategies can support candidate progression from discovery through IND-enabling studies. The session will explore how in vitro and in vivo pharmacology studies can inform translational assessment, along with key considerations for designing IND-enabling DMPK and nonclinical safety programs. Attendees will also learn how study execution can be aligned with key regulatory milestones for US and European submissions.

Key Learning Objectives:

Understand best practices for integrating discovery, DMPK, and nonclinical safety strategies in metabolic drug development.
Learn how in vitro and in vivo studies can support candidate evaluation and translational predictability.
Explore key considerations for designing IND-enabling DMPK and toxicology programs for metabolic therapeutics.
Understand regulatory expectations and map nonclinical development milestones for US and European submissions.

Who Should Attend:

Metabolic disease drug discovery scientists
Translational scientists and pharmacologists
DMPK, ADME, and PK/PD scientists
Toxicologists and nonclinical safety scientists
Preclinical development scientists, regulatory strategists, and project leaders

Sponsored by:

Speakers

Bin Liu, Ph.D.
Scientific Director, WuXi Biology
WuXi AppTec

Mengqi Zhang, Ph.D.
Senior Researcher,
WuXi AppTec

Registration

Forwarded this event? Clear the form

Email Address*

Salutation

First Name*

Last Name*

Company*

Job Title*

Address 1*

City*

State*

Zip / Post Code*

Country/Territory/Area*

Business Phone*

What stage is your most advanced metabolic disease program currently in?*

In which preclinical areas are you currently seeking external support or expertise for your programs?*

In vitro & In vivo DMPK

Non-clinical Toxicology and Safety Assessment

IND-enabling study design and package preparation

Regulatory submission strategy (US FDA / EMA)

None at the moment

When is your organization planning its next IND submission or major preclinical milestone for a metabolic program? *

I would like to receive C&EN’s weekly newsletter with the latest in chemistry news

I would like to receive more information on products and services from the American Chemical Society

address2

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.